HRP20010262A2 - Therapy for improving cognition - Google Patents
Therapy for improving cognition Download PDFInfo
- Publication number
- HRP20010262A2 HRP20010262A2 HR20010262A HRP20010262A HRP20010262A2 HR P20010262 A2 HRP20010262 A2 HR P20010262A2 HR 20010262 A HR20010262 A HR 20010262A HR P20010262 A HRP20010262 A HR P20010262A HR P20010262 A2 HRP20010262 A2 HR P20010262A2
- Authority
- HR
- Croatia
- Prior art keywords
- atypical antipsychotic
- preparation
- patients suffering
- acetylcholinesterase inhibitor
- active ingredient
- Prior art date
Links
- 230000019771 cognition Effects 0.000 title claims description 8
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 239000004480 active ingredient Substances 0.000 claims description 22
- 239000003693 atypical antipsychotic agent Substances 0.000 claims description 22
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 22
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 18
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims description 17
- 208000024827 Alzheimer disease Diseases 0.000 claims description 15
- 206010012289 Dementia Diseases 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 11
- 208000028017 Psychotic disease Diseases 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 9
- 230000002411 adverse Effects 0.000 claims description 9
- 229960003980 galantamine Drugs 0.000 claims description 9
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims description 9
- 229960001534 risperidone Drugs 0.000 claims description 8
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 8
- 229940127236 atypical antipsychotics Drugs 0.000 claims description 6
- 230000009286 beneficial effect Effects 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 206010001497 Agitation Diseases 0.000 claims description 3
- 208000008454 Hyperhidrosis Diseases 0.000 claims description 3
- 206010028813 Nausea Diseases 0.000 claims description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 3
- 206010047700 Vomiting Diseases 0.000 claims description 3
- 238000013019 agitation Methods 0.000 claims description 3
- 230000001149 cognitive effect Effects 0.000 claims description 3
- 230000006866 deterioration Effects 0.000 claims description 3
- 206010022437 insomnia Diseases 0.000 claims description 3
- 230000008693 nausea Effects 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 230000035900 sweating Effects 0.000 claims description 3
- 230000002195 synergetic effect Effects 0.000 claims description 3
- 230000008673 vomiting Effects 0.000 claims description 3
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 claims description 2
- 208000027776 Extrapyramidal disease Diseases 0.000 claims description 2
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims description 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims description 2
- 229960003530 donepezil Drugs 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 229960003162 iloperidone Drugs 0.000 claims description 2
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 claims description 2
- 229960005017 olanzapine Drugs 0.000 claims description 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 2
- 229960004431 quetiapine Drugs 0.000 claims description 2
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims description 2
- 229960004136 rivastigmine Drugs 0.000 claims description 2
- 238000009097 single-agent therapy Methods 0.000 claims description 2
- 229960000607 ziprasidone Drugs 0.000 claims description 2
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims 9
- 230000009931 harmful effect Effects 0.000 claims 2
- 150000007513 acids Chemical class 0.000 description 6
- -1 for example Chemical class 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960002024 galantamine hydrobromide Drugs 0.000 description 1
- QORVDGQLPPAFRS-XPSHAMGMSA-N galantamine hydrobromide Chemical compound Br.O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 QORVDGQLPPAFRS-XPSHAMGMSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98203454 | 1998-10-16 | ||
| PCT/EP1999/007804 WO2000023057A2 (en) | 1998-10-16 | 1999-10-12 | Atypical antiphsychotic in combination with acetylcholinesterase inhibitor for improving cognition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20010262A2 true HRP20010262A2 (en) | 2002-06-30 |
Family
ID=8234219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20010262A HRP20010262A2 (en) | 1998-10-16 | 2001-04-10 | Therapy for improving cognition |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1121131A2 (no) |
| JP (1) | JP2002527469A (no) |
| KR (1) | KR20010072878A (no) |
| CN (1) | CN1367697A (no) |
| AU (1) | AU6472799A (no) |
| BG (1) | BG105302A (no) |
| BR (1) | BR9914419A (no) |
| CA (1) | CA2345767A1 (no) |
| EE (1) | EE200100136A (no) |
| HK (1) | HK1039745A1 (no) |
| HR (1) | HRP20010262A2 (no) |
| HU (1) | HUP0103781A3 (no) |
| ID (1) | ID28441A (no) |
| IL (1) | IL142588A0 (no) |
| NO (1) | NO20011403D0 (no) |
| PL (1) | PL348107A1 (no) |
| SK (1) | SK4592001A3 (no) |
| TR (1) | TR200101082T2 (no) |
| WO (1) | WO2000023057A2 (no) |
| ZA (1) | ZA200103081B (no) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0102841D0 (en) * | 2001-02-05 | 2001-03-21 | Novartis Ag | Organic compounds |
| AU2006201188B2 (en) * | 2001-02-05 | 2007-11-15 | Novartis Ag | New use of iloperidone |
| ES2358416T3 (es) | 2001-10-30 | 2011-05-10 | Novartis Ag | Formulaciones de liberación prolongada de iloperidona y polímero en forma de estrella. |
| GB0216416D0 (en) | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
| US20040192754A1 (en) * | 2003-03-24 | 2004-09-30 | Shapira Nathan Andrew | Methods for treating idiopathic hyperhidrosis and associated conditions |
| TW200501962A (en) * | 2003-04-01 | 2005-01-16 | Novartis Ag | Use of carbamazepine derivatives for the treatment of agitation in dementia patients |
| WO2005065645A2 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Donepezil formulations |
| JP2008523058A (ja) * | 2004-12-10 | 2008-07-03 | アボット・ラボラトリーズ | 縮合ビシクロ複素環置換キヌクリジン誘導体 |
| WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
| US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| CN101668525A (zh) | 2007-03-01 | 2010-03-10 | 前体生物药物股份公司 | 谷氨酰胺酰环化酶抑制剂的新用途 |
| EP2142514B1 (en) | 2007-04-18 | 2014-12-24 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
| MX2007008642A (es) * | 2007-07-16 | 2009-02-25 | World Trade Imp Export Wtie Ag | Composicion farmaceutica que comprende la combinacion de un agente derivado benzisoxazolico y un agente inhibidor reversible de la enzima colinesterasa, indicada para el control y tratamiento de trastornos psicoticos y demencias. |
| BR112012019923A2 (pt) | 2010-02-09 | 2016-08-09 | Univ Johns Hopkins | métodos e composições para melhorar a função cognitiva |
| ES2586231T3 (es) | 2010-03-03 | 2016-10-13 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| DK2545047T3 (da) | 2010-03-10 | 2014-07-28 | Probiodrug Ag | Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5) |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
| CA2891122C (en) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| EP2968220B1 (en) | 2013-03-15 | 2021-05-05 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
| CN107810002B (zh) | 2015-05-22 | 2021-01-05 | 艾吉因生物股份有限公司 | 左乙拉西坦的延时释放药物组合物 |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5336675A (en) * | 1991-05-14 | 1994-08-09 | Ernir Snorrason | Method of treating mania in humans |
| DK0584185T3 (da) * | 1991-05-14 | 2000-02-07 | Ernir Snorrason | Behandling af træthedssyndrom med cholinesteraseinhibitorer |
| CA2300148C (en) * | 1997-08-11 | 2009-06-23 | University Of South Florida | Nicotine antagonists for nicotine-responsive neuropsychiatric disorders |
| PT1073432E (pt) * | 1998-04-14 | 2007-10-22 | Gen Hospital Corp | Utilização da d-alanina ou da d-serina para o tratamento da esquizofrenia |
-
1999
- 1999-10-12 BR BR9914419-0A patent/BR9914419A/pt not_active IP Right Cessation
- 1999-10-12 CN CN99812184A patent/CN1367697A/zh active Pending
- 1999-10-12 AU AU64727/99A patent/AU6472799A/en not_active Abandoned
- 1999-10-12 EP EP99952580A patent/EP1121131A2/en not_active Withdrawn
- 1999-10-12 ID IDW20010828A patent/ID28441A/id unknown
- 1999-10-12 HU HU0103781A patent/HUP0103781A3/hu unknown
- 1999-10-12 TR TR2001/01082T patent/TR200101082T2/xx unknown
- 1999-10-12 PL PL99348107A patent/PL348107A1/xx unknown
- 1999-10-12 EE EEP200100136A patent/EE200100136A/xx unknown
- 1999-10-12 SK SK459-2001A patent/SK4592001A3/sk unknown
- 1999-10-12 KR KR1020017002286A patent/KR20010072878A/ko not_active Application Discontinuation
- 1999-10-12 WO PCT/EP1999/007804 patent/WO2000023057A2/en not_active Application Discontinuation
- 1999-10-12 JP JP2000576832A patent/JP2002527469A/ja not_active Withdrawn
- 1999-10-12 CA CA002345767A patent/CA2345767A1/en not_active Abandoned
- 1999-10-12 IL IL14258899A patent/IL142588A0/xx unknown
-
2001
- 2001-03-01 BG BG105302A patent/BG105302A/xx unknown
- 2001-03-20 NO NO20011403A patent/NO20011403D0/no not_active Application Discontinuation
- 2001-04-10 HR HR20010262A patent/HRP20010262A2/hr not_active Application Discontinuation
- 2001-04-12 ZA ZA200103081A patent/ZA200103081B/en unknown
-
2002
- 2002-01-10 HK HK02100158.6A patent/HK1039745A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1367697A (zh) | 2002-09-04 |
| TR200101082T2 (tr) | 2001-09-21 |
| SK4592001A3 (en) | 2001-12-03 |
| NO20011403L (no) | 2001-03-20 |
| ZA200103081B (en) | 2002-07-12 |
| NO20011403D0 (no) | 2001-03-20 |
| JP2002527469A (ja) | 2002-08-27 |
| BR9914419A (pt) | 2001-06-26 |
| HUP0103781A2 (hu) | 2002-03-28 |
| WO2000023057A3 (en) | 2000-07-27 |
| IL142588A0 (en) | 2002-03-10 |
| EE200100136A (et) | 2002-06-17 |
| PL348107A1 (en) | 2002-05-06 |
| CA2345767A1 (en) | 2000-04-27 |
| WO2000023057A2 (en) | 2000-04-27 |
| AU6472799A (en) | 2000-05-08 |
| EP1121131A2 (en) | 2001-08-08 |
| BG105302A (en) | 2001-11-30 |
| HUP0103781A3 (en) | 2003-09-29 |
| HK1039745A1 (zh) | 2002-05-10 |
| ID28441A (id) | 2001-05-24 |
| KR20010072878A (ko) | 2001-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20010262A2 (en) | Therapy for improving cognition | |
| US6444665B1 (en) | Method for treating pain | |
| CN102046192B (zh) | GnRH相关化合物的组合物及制备方法 | |
| CA2166204C (en) | Pharmaceutical compositions for sparingly soluble therapeutic agents | |
| KR102061486B1 (ko) | 에키노칸딘 계열의 화합물에 대한 투여 용법 | |
| AP2000001943A0 (en) | Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent and use of this absorption-promoting agent. | |
| JP6856315B2 (ja) | スクリーンフォーマー用の外用組成物 | |
| YU66600A (sh) | Farmaceutski preparati koji mogu da budu gelirani | |
| CA2288143A1 (en) | Activated protein c formulations | |
| RU93004484A (ru) | Производные пиразола, способ их получения и содержащие их фармацевтические композиции | |
| US20040019074A1 (en) | Pharmaceutical compositions for sparingly soluble therapeutic agents | |
| IL158903A0 (en) | Use of sulodexide for the treatment of inflammatory bowel disease | |
| KR20070024722A (ko) | 저작에 대하여 안정적인 캡슐 | |
| JP2022513556A (ja) | κオピオイド受容体作動薬の経口製剤 | |
| JP2003500441A (ja) | １−［４−（５−シアノインドール−３−イル）ブチル］−４−（２−カルバモイル−ベンゾフラン−５−イル）−ピペラジンおよびこの生理学的に受け入れられる塩の新規な使用 | |
| JP2000290199A (ja) | 経口用医薬組成物 | |
| HU206833B (en) | Process for producing pharmaceutical compositions containing calcitoninogen-like peptide-amide or pharmaceutically acceptable salt thereof for treating erective disfunctions | |
| EP2862572A1 (en) | Prophylactic and/or therapeutic agent for mild cognitive impairment | |
| JPWO2004066998A1 (ja) | 安定な経口用固形医薬組成物 | |
| JP2019501861A (ja) | 水不溶性またはわずかに水溶性の薬剤の水可溶性を改善するための方法 | |
| JP3719340B2 (ja) | クリーム状洗浄剤組成物 | |
| US20210386728A1 (en) | Compositions and methods for intrathecal administration of mcoppb for pain relief | |
| CA2386583A1 (en) | Novel combination for the treatment of sexual dysfunction | |
| EP0671908B1 (en) | Pharmaceutical compositions comprising 5-ht 1? receptor agonists and absorption enhancers | |
| JP2010529028A (ja) | 骨破壊の処置のためのｈｄａｃ阻害剤の使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20011012 Year of fee payment: 3 |
|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| OBST | Application withdrawn |